Harmonized diagnostic criteria for Alzheimer's disease: recommendations

Two major sets of criteria for the clinical diagnosis of Alzheimer's disease (AD) recently have been published, one from an International Working Group (IWG) and the other from working groups convened by the National Institute on Aging (NIA) and the Alzheimer's Association (AA) in the United States. These criteria both aim to support a clinical diagnosis with in vivo evidence of AD pathology, using imaging methods and detection of biofluid biomarkers, and emphasize an aetiological diagnosis even in the prodromal stages of the disorder. Nonetheless, there are substantial differences in these two sets of criteria.

[1]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[2]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[3]  A. Fagan,et al.  Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. , 2013, JAMA neurology.

[4]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[5]  H. Brodaty,et al.  Early dementia diagnosis and the risk of suicide and euthanasia , 2010, Alzheimer's & Dementia.

[6]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[7]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[8]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[9]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[10]  F. Barkhof,et al.  New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population , 2010, Dementia and Geriatric Cognitive Disorders.

[11]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[12]  B. Winblad,et al.  Lack of Accuracy for the Proposed ‘Dubois Criteria’ in Alzheimer’s Disease: A Validation Study from the Swedish Brain Power Initiative , 2010, Dementia and Geriatric Cognitive Disorders.

[13]  K. Segers,et al.  What Belgian Neurologists and Neuropsychiatrists Tell Their Patients With Alzheimer Disease and Why: A National Survey , 2009, Alzheimer disease and associated disorders.

[14]  J. Morris,et al.  Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview , 2011, Neurobiology of Aging.

[15]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[16]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[17]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[18]  Christer Halldin,et al.  Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.

[19]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[20]  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Neurology.

[21]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[22]  L. Harrell,et al.  Impaired financial abilities in mild cognitive impairment , 2003, Neurology.

[23]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[24]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[25]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[26]  D. Harvey,et al.  MCI is Associated With Deficits in Everyday Functioning , 2006, Alzheimer disease and associated disorders.

[27]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[28]  C. Fabrigoule,et al.  Restriction in complex activities of daily living in MCI , 2006, Neurology.

[29]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[30]  C. Xiong,et al.  Reaction to a Dementia Diagnosis in Individuals with Alzheimer's Disease and Mild Cognitive Impairment , 2008, Journal of the American Geriatrics Society.

[31]  D. Perani,et al.  Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis: Report of 2 Cases , 2010, Alzheimer disease and associated disorders.

[32]  J. Morris,et al.  Early-Stage Alzheimer Disease Represents Increased Suicidal Risk in Relation to Later Stages , 2005, Alzheimer disease and associated disorders.

[33]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[34]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[35]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[36]  Pei-Ning Wang,et al.  Family members favor disclosing the diagnosis of Alzheimer's disease , 2005, International Psychogeriatrics.

[37]  M. Gallant,et al.  Spouse Caregivers' Attitudes Toward Obtaining a Diagnosis of a Dementing Illness , 1996, Journal of the American Geriatrics Society.

[38]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[39]  C. Rowe,et al.  Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[40]  E. Peskind,et al.  Suicide in Two Patients with Alzheimer's Disease , 1995, Journal of the American Geriatrics Society.

[41]  G. Frisoni,et al.  The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment , 2010, Alzheimer's & Dementia.

[42]  Y. Conwell,et al.  Hospital-diagnosed dementia and suicide: a longitudinal study using prospective, nationwide register data. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[43]  Susan M Resnick,et al.  Changes in Brain Function Occur Years before the Onset of Cognitive Impairment , 2013, The Journal of Neuroscience.

[44]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[45]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[46]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[47]  R. Coleman,et al.  Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .

[48]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[49]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[50]  A. Fagan,et al.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. , 2012, Biomarkers in medicine.

[51]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .